Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the year ended December 31, 2021 and provided a corporate update on key events since the start of 2021.
March 31, 2022
· 13 min read